Provided by Tiger Trade Technology Pte. Ltd.

Prime Medicine, Inc.

3.59
-0.0200-0.55%
Pre-market: 3.670.0800+2.23%04:29 EDT
Volume:2.09M
Turnover:7.46M
Market Cap:648.03M
PE:-3.31
High:3.64
Open:3.54
Low:3.46
Close:3.61
52wk High:6.94
52wk Low:2.67
Shares:180.51M
Float Shares:116.00M
Volume Ratio:0.87
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0853
EPS(LYR):-1.3521
ROE:-373.29%
ROA:-46.52%
PB:16.28
PE(LYR):-2.66

Loading ...

Prime Medicine Price Target Maintained with a $7.00/Share by Chardan Capital

Dow Jones
·
Aug 25

Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)

TIPRANKS
·
Aug 25

Prime Medicine Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 10

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cresco Labs (OtherCRLBF), Prime Medicine, Inc. (PRME) and Steris (STE)

TIPRANKS
·
Aug 07

NextCure Q2 Net Loss Narrows on Lower Expenses

Reuters
·
Aug 07

INmune Bio Q2 Net Loss Narrows on Lower Impairment Charges

Reuters
·
Aug 07

Prime Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Prime Medicine Publishes Corporate Presentation on Prime Editing Platform, Liver Disease Pipeline Focus

Reuters
·
Aug 06

Prime Medicine, Inc. Q2 EPS USD -0.24

Reuters
·
Aug 06

Prime Medicine Q2 FY26 Net Loss Narrows to $42.1 Million

Reuters
·
Aug 06

Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate

Benzinga Earnings
·
Aug 06

Press Release: Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
Aug 06

Prime Medicine, Inc. Q2 Income from Operations USD -43.285 Million

THOMSON REUTERS
·
Aug 06

Prime Medicine, Inc: Expects Cash and Investments as of June 30, 2026 Sufficient to Fund Operations into 2027

THOMSON REUTERS
·
Aug 06

Scribe's Genetic Editing Aims to Prevent Heart Attacks

Dow Jones
·
Jul 30

Prime Medicine Says FDA Clears IND for Pm577a in Wilson Disease Trial

Reuters
·
Jul 24

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for Pm577a in H1069q-mutated Wilson Disease

THOMSON REUTERS
·
Jul 24

Prime Medicine, - Phase 1/2 Trial for Pm577a Expected to Start in H2 2026 with Initial Data in 2027

THOMSON REUTERS
·
Jul 24

LifeSci Capital Remains a Buy on Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jul 11

Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025

Dow Jones
·
Jul 10